Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Senators Allege Lilly’s Promised Insulin Cap Not in Effect Everywhere

  • Post author:PacConAdmin
  • Post published:July 14, 2023
  • Post category:Drug Industry Daily

Eli Lilly’s generic insulin Lispro can cost nearly four times as much as the company’s promised price of $25 per vial, according to a new report from Democratic Senators Elizabeth…

Continue ReadingSenators Allege Lilly’s Promised Insulin Cap Not in Effect Everywhere

HHS Secretary Cautions Industry on COVID-19 Vaccine Prices

  • Post author:PacConAdmin
  • Post published:July 14, 2023
  • Post category:Drug Industry Daily

With COVID-19 vaccines moving to the open market postpandemic, their manufacturers should remember the support they received from the federal government when setting prices, said HHS Secretary Xavier Becerra in…

Continue ReadingHHS Secretary Cautions Industry on COVID-19 Vaccine Prices

Preliminary Injunction Sought by Chambers of Commerce in IRA Drug Pricing Suit

  • Post author:PacConAdmin
  • Post published:July 14, 2023
  • Post category:Drug Industry Daily

The U.S. Chamber of Commerce and three other chambers have filed a motion for a preliminary injunction preventing implementation of the Drug Price Negotiation Program in the Inflation Reduction Act…

Continue ReadingPreliminary Injunction Sought by Chambers of Commerce in IRA Drug Pricing Suit

FTC Ponders Issuing Warning Statement to PBMs

  • Post author:PacConAdmin
  • Post published:July 14, 2023
  • Post category:Drug Industry Daily

The FTC will continue its ongoing examination of the pharmacy benefit management (PBM) industry at an open meeting July 20 when it decides whether to issue a warning to PBMs…

Continue ReadingFTC Ponders Issuing Warning Statement to PBMs

Regulatory Update — Week of July 10, 2023

  • Post author:PacConAdmin
  • Post published:July 14, 2023
  • Post category:Drug Industry Daily

Over the past week, the FDA has issued draft guidances on inborn errors of metabolism, clinical trial postmarketing studies and human cellular and gene therapy products. Source: Drug Industry Daily

Continue ReadingRegulatory Update — Week of July 10, 2023

FDA Clarifies When It’s OK to Miss Postmarketing Requirement Milestones

  • Post author:PacConAdmin
  • Post published:July 13, 2023
  • Post category:Drug Industry Daily

In an effort to improve adherence with postmarketing requirements (PMR), the FDA has laid out the circumstances under which noncompliance with PMRs is justified in a new draft guidance. Source:…

Continue ReadingFDA Clarifies When It’s OK to Miss Postmarketing Requirement Milestones

Managing Manufacturing Changes of Gene Therapy Products is Focus of Draft Guidance

  • Post author:PacConAdmin
  • Post published:July 13, 2023
  • Post category:Drug Industry Daily

Acknowledging the complexity of human cellular and gene therapy (CGT) products, the FDA has written a draft guidance intended to help manufacturers manage and report changes in products, based on…

Continue ReadingManaging Manufacturing Changes of Gene Therapy Products is Focus of Draft Guidance

Merck Seeks Summary Judgment in IRA Drug Pricing Suit

  • Post author:PacConAdmin
  • Post published:July 13, 2023
  • Post category:Drug Industry Daily

Merck has asked a federal judge to issue an order granting a summary judgment in its case against HHS over the Inflation Reduction Act (IRA) on the grounds that “no…

Continue ReadingMerck Seeks Summary Judgment in IRA Drug Pricing Suit

ICER Affirms Sickle Cell Disease Gene Therapies Cost-Effective at $2 Million

  • Post author:PacConAdmin
  • Post published:July 13, 2023
  • Post category:Drug Industry Daily

A revised report from the Institute for Clinical Evaluation and Research (ICER) has reiterated that two experimental gene therapies for sickle cell disease (SCD) would likely be cost-effective if priced…

Continue ReadingICER Affirms Sickle Cell Disease Gene Therapies Cost-Effective at $2 Million

Thoughts on the Implications of FDA Approval of OTC Birth Control

  • Post author:PacConAdmin
  • Post published:July 13, 2023
  • Post category:Drug Industry Daily

FDA’s decision to approve the OTC status of the birth control pill is a real milestone in the evolution of Rx-to-OTC switches. Source: Drug Industry Daily

Continue ReadingThoughts on the Implications of FDA Approval of OTC Birth Control
  • 1
  • 2
  • 3
  • 4
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.